2020年新冠病毒爆發(fā)，人們在經(jīng)歷了這樣一場醫(yī)療戰(zhàn)役之后，對現(xiàn)今醫(yī)療手段有了更多的認識。在漫長的人類進化過程和與疾病的對抗過程中，醫(yī)療手段不斷的升級換代，從藥物治療、手術治療發(fā)展到了一個新的階段、新的領域——細胞療法。細胞療法作為第三代醫(yī)療手段，不論是利用自身細胞抗癌的“過繼性免疫細胞治療”，還是萬能的“干細胞療法”，都展現(xiàn)出巨大的前景。
本文對細胞療法的發(fā)展做一綜述，并對細胞治療產(chǎn)品的特點和臨床試驗相關檢測進行簡要介紹。
圖1 免疫細胞療法的技術更新
圖2 DCs與CIK細胞相互作用的簡化方案，成熟的DCs還能與NK細胞作用
圖3 CAR的結構示意圖
圖4 全球獲批CAR-T治療產(chǎn)品
圖5 造血細胞譜系的應用和疾病治療潛力
圖6 干細胞技術的應用多樣性
圖7 已獲批的干細胞產(chǎn)品（數(shù)據(jù)截止2020.3）
圖8 外周血CAR - T細胞動力學
[1] 黃迪, 龔暢, 宋爾衛(wèi)等. 從“個體化”到“精準化”的腫瘤免疫細胞治療[J]. 生命科學, 2019, (31-7): 651-659.
[2] 劉曉燕. 干細胞療法——喜憂參半的前景展望[J]. 中國美容整形外科雜志, 2019, 30(4):193-196.
[3] 陸輝, 王冰, 祁興順等. 干細胞文獻匯總分析[J]. 醫(yī)學信息, 2019(32-24), 32-46.
[4] Alexander T, Farge D, Badoglio M, et al． Hematopoietic stem cell therapy for autoimmune diseases: clinical experience and mechanisms [J]． Autoimmun, 2018, 92: 35-46．
[5] Jakovljevic J, Harrell CR, Fellabaum C, et al．Modulation of autophagy as new approach in mesenchymal stem cell based therapy [J]．Biomed Pharmacother, 2018, 104: 404-410．
[6] Vieira MS, Santos AK, Vasconcellos R, et al．Neural stem cell differentiation into mature neurons: mechanisms of regulation and biotechnological applications [J]. Biotechnol Adv, 2018, 36(7): 1946-1970．
[7] Chu GY, Chen YF, Chen HY, et al． Stem cell therapy on skin: mechanisms, recent advances and drug reviewing issues [J]. Food Drug Anal, 2018, 26(1): 14-20．
[8] FDA, Preclinical Assessment of Investigational Cellular and Gene Therapy Products. 2013.
[9] FDA, Potency Tests for Cellular and Gene Therapy Products, 2011.
[10] Milone MC, Bhoj VG. The pharmacology of T cell therapies [J]. Mol Ther Methods Clin Dev. 2018, 8: 210-21.
[11] Locke FL, Neelapu SS, Bartlett NL，et al． Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma [J]. Mol Ther. 2017, 25(1): 285-295.
[12] Suzanne R, Thibodeaux, Michael C. Milone, et al．Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory [J]. Clinical Chemistry 2019, 65(4): 519–529.
[13] Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy assessment and management of toxicities [J]. Nat Rev Clin Oncol,2017,15(1): 47-62.
[14] Paula Mosin ska, Agata Gabryelska, Malwina Zasada，et al．Dual Functional Capability of Dendritic Cells – Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy [J]. Frontiers in Pharmacology, 2017, 8:126.
[15] Wai Feng Lim, Tomoko Inoue-Yokoo, Keai Sinn Tan，et al． Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells [J]. Stem Cell Research & Therapy, 2013, 4:71.
